Every gene tells a story, written in the language of DNA and read by RNA. But sometimes, that story contains errors – genetic mutations that lead to disease. Antisense oligonucleotides (ASOs) offer a way to “reframe” the story before and while it’s read, by binding directly to RNA and either changing the way it’s being read or by re-emphasizing different parts of said story.
As of April 2026, ASOs remain the largest commercially established oligonucleotide drug subclass, with 10 unique ASO medicines approved by the FDA and/or EMA.
ASOs are short, synthetic strands of DNA or RNA, designed to recognize specific RNA sequences through base pairing.
Once an ASO binds to its target RNA, it can:
Each approach uses the same principle: precise molecular recognition to silence or modify genetic messages at the RNA level.
Developing an ASO requires balancing specificity, stability, and delivery. Chemical modifications (such as phosphorothioate backbones or 2’-O-methyl sugars) improve durability and cellular uptake, while minimizing off-target effects.
At BioSpring, we help translate ASO design into reality through high,quality, large-scale, GMP manufacturingmanufacturing and analytics – ensuring each molecule performs exactly as intended.
ASOs show how oligonucleotides can be used to influence gene expression with high specificity. By targeting disease at its molecular source, antisense therapies embody the essence of precision medicine and move the elements of life from genetic understanding to clinical impact.